- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03364569
Usefullness of Peri-operative Tranexamic Acid in Primary Breast Augmentation With Implants. (DRAINAGE)
Study Overview
Detailed Description
A total of forty participants were included in this case-control study over a fifteen months period. The participants were divided in two equal groups. The case group (TXA group) was treated with a daily oral administration of two grams of tranexamic acid whereas the control group (noTXA group) was not treated. The data that has been recorded is the gender, the age, the implant volume (cc), the shape of the implant (round or anatomical), the type of surgical pocket (pre-muscular or retro-muscular), the texture of the implant (textured or smooth), the operating time (in minutes), the blood pressure operative average during surgery, volume of fluid daily (right and left) and complications (hematoma, infection, deep vein thrombosis, pulmonary embolism, anaphylaxis and early exposure to implants).
Three investigators were enrolled in the study, including the corresponding author. Two investigators performed the intervention, operating one breast each.
At the end of the surgical procedure, a drain was put in the retro-pectoral space on each breast side. A compressive garment was immediately fitted before the exit of the participant. The participants received oral analgesics according to the hospital guidelines and no thromboprophylaxis was given, as it is a standard recommendation of the French Society of Anaesthesiologists (SFAR).
Oral administration of the TXA had never been tested in breast augmentation indications, and the investigators followed the recommendations of one gram, two times a day, starting at the end of the surgery so as to avoid any adverse effects. The participants received two grams of Spotof ® (C.C.D laboratory, Portugal) as an oral liquid solution during three days.
All participants were interviewed by a nurse every four hours starting at the end of the post-operative recovery room till the exit of their hospital stay. Drain fluid volume in the vacuum devices was recorded every twenty four hours. The drains were removed when production was below forty milliliter per twenty four hours, according to hospital routine. Any early (less than seven days) or late (better than thirty days) post-operative complications were also listed. All participants had a consultation seven days and two months after the surgery according to the department guidelines. A hotline telephone number has been given to participants to facilitate contact if any inconvenient consequences have occurred.
In each sub-group (no TXA and TXA), the main outcome was the drain fluid production during the study which was registered for each breast every twenty four hours after the surgery and at the exit of the participant. Volume were stored and collected in milli-liters (mL) without consistency or color analysis. The age (in years), the implant volume (in milliliters), the shape (round or anatomic) and the texture (smooth or textured), the mean operative time (in minutes), the mean operative arterial pressure (in mmHg) were also recorded as well as the length of the hospital stay (in days). Any surgical complications and any side effects associated to the TXA drug were also listed.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Woman with Primary Breast Augmentation
Exclusion Criteria:
- Past History of Thromboembolism
- Use of anticoagulant or platelet-inhibiting drugs
- Severe Co-morbidity (ASA III)
- Pre-pectoral Implant Pocket Location
- Breast lipofecting
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participant with tranexamic acid.
The investigators followed the recommendations of one gram, two times a day, starting at the end of the surgery so as to avoid any adverse effects.
The participants received two grams of Spotof ® (C.C.D laboratory, Portugal) as an oral liquid solution during three days.
|
Participants with taking tranexamic acid (2 x 1g per day) as a preventive and without adjuvant treatment.
|
Participant without tranexamic acid.
This group concerns participants followed without acid tranexamic treatment.
Investigators will observe the postoperative practices and complications observed, according to the surgical habits.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-operative drainage volume
Time Frame: Through study completion, an average of 2 years.
|
At the end of the surgical procedure, a drain was put in the retro-pectoral space on each breast side.
A compressive garment was immediately fitted before the exit of the patient.
The participants received oral analgesics according to the hospital guidelines and no thromboprophylaxis was given, as it is a standard recommendation of the French Society of Anaesthesiologists (SFAR).
Drain fluid volume in the vacuum devices was recorded every 24 hours.
The drains were removed when production was below 40 mL per 24h, according to hospital routine.
Volume were stored and collected in milli-liters (mL) without consistency or color analysis.
Age (in Years), Implant Volume (in milli-liters), Shape (Round or Anatomic) and Texture (Smooth or Textured), Mean Operative Time (in minutes), Mean Operative Arterial Pressure (in mmHg) were also recorded as well as the length of the Hospital Stay (in Days).
|
Through study completion, an average of 2 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-operative complications
Time Frame: Through study completion, an average of 2 years.
|
The investigators observed postoperative complications.
All participant were interviewed by a nurse every 4 hours starting at the end of the post-operative recovery room till the exit of their hospital stay.
Any early (< 7 days) or late (> 30 days) post-operative complications were also listed.
All the participants had a consultation 7 days and 2 months after the surgery according to the department guidelines.
A Hotline phone number was given to the patients to ease contact if any inconvenient aftermath occured.
Any surgical complications and any side effects associated to the TXA drug were also listed.
|
Through study completion, an average of 2 years.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas COLSON, Centre Hospitalier Rene Dubos
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHRD2315
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plastic Surgery
-
C. R. BardTepha, Inc.CompletedPlastic Surgery | Reconstructive SurgeryUnited States
-
Nantes University HospitalCompletedGynecological Surgery | Plastic Surgery | ENT SurgeryFrance
-
University Hospital, AntwerpCompleted
-
Cedars-Sinai Medical CenterRecruitingOther Reconstructive Surgery | Plastic SurgeryUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of British ColumbiaRecruitingBreast Reconstruction | Mastectomy | Nerve Block | Surgery, PlasticCanada
-
University of British ColumbiaBC Children's Hospital Research Institute; BC Children's Hospital FoundationUnknownVirtual Reality vs. Standard-of-Care for Comfort During Minor Plastic Surgery Procedures in ChildrenMinor Plastic SurgeryCanada
-
NHS Greater Glasgow and ClydeJean Brown Bequest Fund, Glasgow, UKNot yet recruitingTelemedicine | Surgery, PlasticUnited Kingdom
-
Chung-Ang University Hosptial, Chung-Ang University...CompletedAnesthesia, Intravenous; Surgery, PlasticKorea, Republic of
-
University of British ColumbiaWithdrawn
Clinical Trials on Tranexamic acid
-
Icahn School of Medicine at Mount SinaiRecruiting
-
University of LiegeCompletedArthroplasty Complications | Hemorrhage Postoperative | Total Blood LossBelgium
-
London School of Hygiene and Tropical MedicineCompleted
-
Samsung Medical CenterUnknownBleeding | Transfusion Related ComplicationKorea, Republic of
-
Assiut UniversityCompleted
-
Thammasat UniversityCompleted
-
Ferring PharmaceuticalsCompleted
-
Ain Shams UniversityCompleted
-
Aswan University HospitalCompletedCesarean Section ComplicationsEgypt
-
London School of Hygiene and Tropical MedicineRawalpindi Medical CollegeCompletedPregnancy, High RiskPakistan, Zambia